Catalyst
Slingshot members are tracking this event:
BioPharmX Enrolls First Subject in OPAL Phase 2b Clinical Trial of BPX-01 Topical Minocycline for the Treatment of Acne
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BPMX |
|
|
Additional Information
The 12-week, multi-center, double-blind, three-arm, vehicle controlled OPAL study expects to enroll 225 people, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.
The primary efficacy endpoint for the study is mean change from baseline in inflammatory lesion counts at Week 12. The secondary efficacy endpoint is achievement of at least a two-grade reduction in Investigator Global Assessment (IGA) at Week 12 compared to baseline.The company expects results from the OPAL study in the first half of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 24, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Acne, Opal Phase 2b, Bpx-01, Bpx-01 Minocycline